The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing
The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share...
From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure
The story, briefly The math, meaning what the filed numbers actually show, tells a story of...
ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not
Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in....
Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.
The share price is up 72% over the past twelve months. Revenue has fallen every single...
Half the Price, Twice the Story: What Insmed’s Numbers Actually Say
A year ago, Insmed traded above $210. Today it sits near $105, cut in half, even...
TGTX: The Drug Is Working. The Question Is What the Market Has Already Priced In.
Three years ago, TG Therapeutics had almost no revenue and a stock that traded mostly on...
Meta is spending like a startup and priced like a blue chip. One of those has to give.
The story, briefly Meta's ads business is growing at a pace that would be remarkable for...
Pacira BioSciences: A Billion-Dollar Drug Company Priced Like a Rumor
First, the shape of it Pacira's filed numbers show a company generating three-quarters of a billion...
Biogen’s stock has climbed 65% in a year. Its earnings have not.
Five years ago, Biogen bet the company on a drug most neurologists did not believe in....
Apple at $336: The Business Is Growing. The Price Assumes It Never Stops.
First, the shape of it Apple's filed numbers show a business that earned more per dollar...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.